NCT06735027 Corticosteroid Injection Versus Nerve Block
| NCT ID | NCT06735027 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Minnesota |
| Condition | Glenohumeral Arthritis |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2025-01-02 |
| Primary Completion | 2027-01-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2025-01-02 with a primary completion date of 2027-01-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to evaluate conservative pain relief measures for patients suffering from glenohumeral arthritis or rotator cuff arthropathy. Conservative management of osteoarthritis is often first line treatment, and while a corticosteroid injection is frequently used, suprascapular nerve blocks have not often been described as an analgesic option in this population.
Eligibility Criteria
Inclusion Criteria: * diagnosis of glenohumeral osteoarthritis, rheumatoid arthritis, or rotator cuff arthropathy who are being offered injection Exclusion Criteria: * uncontrolled diabetes (patients will be excluded if no HbA1c within a year or if it is 8 or greater" * known allergy to steroid or anesthetic * pregnant women * prisoners * patients with diminished capacity to consent to participation * children under 18 years of age * non-English speakers
Contact & Investigator
Allison Rao, MD
PRINCIPAL INVESTIGATOR
University of Minnesota
Frequently Asked Questions
Who can join the NCT06735027 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 99 Years, studying Glenohumeral Arthritis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06735027 currently recruiting?
Yes, NCT06735027 is actively recruiting participants. Contact the research team at rao00149@umn.edu for enrollment information.
Where is the NCT06735027 trial being conducted?
This trial is being conducted at Minneapolis, United States.
Who is sponsoring the NCT06735027 clinical trial?
NCT06735027 is sponsored by University of Minnesota. The principal investigator is Allison Rao, MD at University of Minnesota. The trial plans to enroll 40 participants.